Generic Name and Formulations:
Cyclobenzaprine HCl 15mg, 30mg; ext-rel caps.
Indications for AMRIX:
Adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions.
Take at same time each day. 15mg once daily; may increase to 30mg/day given once daily. Max 2–3 weeks. Elderly or hepatic impairment: not recommended.
Acute post-MI. Arrhythmias, heart block, other conduction disturbances. CHF. Hyperthyroidism. During or within 14 days of MAOIs.
Not effective in treating spasticity associated with cerebral or spinal chord disease or in children with cerebral palsy. Urinary retention. Angle-closure glaucoma. Increased intraocular pressure. Hepatic impairment or elderly: not recommended. Pregnancy (Cat.B). Nursing mothers.
Muscle relaxant (central).
See Contraindications. Hypertensive crisis with MAOIs. Increased risk of serotonin syndrome with other serotonergic drugs (eg, SSRIs, SNRIs, tricyclic antidepressants, tramadol, bupropion, meperidine, verapamil, MAOIs); discontinue if occurs. Potentiates anticholinergics, alcohol, other CNS depressants. May antagonize guanethidine, clonidine. May enhance seizure risk with concomitant tramadol.
Drowsiness, dry mouth, dizziness, fatigue, headache, somnolence, constipation, nausea, dyspepsia, dysgeusia, tremor, nervousness, asthenia, blurred vision, confusion.
Clinical Pain Advisor Articles
- Radiofrequency Denervation Efficacious in Treating Thoracic Zygapophyseal Joint Pain
- Prescribed Opioids Difficulties Scale Effective for Assessing Concerns of Patients With Chronic Pain
- Predictors of Opioid Overdose in High-Risk Users
- Optimal Strategies for Opioid Weaning After Ambulatory Surgery
- Emergency Physicians Offer Recommendations for Identifying and Managing Opioid Use Disorder
- Consensus Guidelines for the Use of Intravenous Ketamine for Chronic Pain
- Pain Societies Issue Guidelines on Use of Ketamine for the Management of Acute Pain
- Labor Epidural Analgesia Linked to Reduced Likelihood of Successful Breastfeeding
- Novel Oral Treatment Safe, Effective for Migraine Headache Relief
- DFN-02 Nasal Spray Safe, Effective for Acute Treatment of Episodic Migraine
- Higher PainDETECT Scores, Neuropathic Pain Preoperatively May Increase Risk for Chronic Pain Post-TKR
- Terms Used for Addiction May Be Associated With Explicit, Implicit Bias
- Erenumab Reduces Monthly Migraine Days in Patients With Treatment-Resistant Migraine
- Government and Industry Lead the Way in Funding USPSTF Systematic Reviews
- Communication-Based Intervention Increases Goals-of-Care Discussions Between Physicians, Patients With Serious Illness